AstraZeneca has denied ongoing takeover talks with US rival Bristol Myers Squibb, a move that follows a significant share price drop and subsequent recovery. The situation highlights questions about AstraZeneca's long-term M&A strategy under CEO Sir Pascal Soriot.
AstraZeneca et Bristol Myers Squibb ont entamé des discussions en vue d'une fusion potentielle, ce qui pourrait créer le quatrième acteur mondial de la pharmacie avec plus de 100 milliards de dollars de CA.
More than £17bn was wiped off AstraZeneca's market value after reports it is discussing a takeover of US rival Bristol Myers Squibb in a potential $400bn deal.
AstraZeneca CEO Sir Pascal Soriot, 67, is under scrutiny for a potential $400bn merger with Bristol Myers Squibb, which could jeopardize his legacy and expose the company to debt and patent cliff risks.
AstraZeneca's shares fell over £17bn after reports of talks to acquire US rival Bristol Myers Squibb, potentially creating a near $400bn pharmaceutical group. Analysts and shareholders question the deal's rationale due to regulatory hurdles and portfolio overlap.
AstraZeneca y Bristol Myers Squibb negocian una fusión valorada en casi 400.000 millones de dólares, lo que crearía uno de los mayores grupos farmacéuticos globales. La noticia genera dudas entre analistas sobre la lógica estratégica y posibles monopolios.
AstraZeneca ve Bristol Myers Squibb, olası bir birleşme için görüşmeler yürüttüklerini doğruladı. Yaklaşık 400 milyar dolarlık piyasa değeriyle ilaç sektörünün en büyük anlaşmalarından biri olabilecek bu birleşme, AstraZeneca yatırımcıları arasında hisse düşüşü ve stratejik endişelere neden oldu.
AstraZeneca shares fell after reports of potential merger talks with Bristol Myers Squibb, a deal analysts questioned given AZ's strong growth and BMS's looming patent expirations, despite potential oncology synergies.
AstraZeneca's shares fell sharply after reports of potential merger talks with Bristol Myers Squibb, a deal analysts questioned given AstraZeneca's strong growth trajectory and Bristol Myers' impending patent expirations.
Un pilote de ligne de 39 ans a été arrêté à l'aéroport de Jakarta avec 70 000 comprimés d'ecstasy après un vol depuis Kuala Lumpur, risquant la peine de mort selon la police.
AstraZeneca e Bristol Myers Squibb stanno negoziando una fusione che creerebbe il quarto colosso farmaceutico mondiale con quasi 400 miliardi di dollari di capitalizzazione. I colloqui, riferiti dal Financial Times, potrebbero concludersi con un accordo, sebbene ritardi o fallimenti siano possibili.
Britain’s AstraZeneca is reportedly in discussions to acquire US rival Bristol Myers Squibb, a deal potentially creating a nearly $400bn pharmaceutical group. The news caused AstraZeneca's shares to drop, while BMS's rose, with analysts questioning the rationale and regulatory hurdles.
AstraZeneca e Bristol Myers Squibb sarebbero in trattativa per una fusione che creerebbe il quarto colosso farmaceutico mondiale con una capitalizzazione vicina ai 400 miliardi di dollari, secondo quanto riportato dal Financial Times.
AstraZeneca und Bristol Myers Squibb verhandeln über eine Fusion, die einen der größten Pharmakonzerne der Welt mit einem Börsenwert von fast 400 Milliarden Dollar entstehen lassen würde.
U.K. pharmaceutical giant AstraZeneca is reportedly discussing a potential $400 billion merger with U.S. competitor Bristol Myers Squibb, a deal that would be one of the largest in history, according to the Financial Times.
Der britische Pharmakonzern AstraZeneca prüft laut einem Zeitungsbericht eine Fusion mit dem US-Konkurrenten Bristol Myers Squibb. Die Gespräche könnten zu einem der größten Pharmakonzerne weltweit führen, aber auch scheitern.
AstraZeneca's Q2 net profit rose 2% to $2.51 billion, beating analyst expectations, driven by strong cancer medicine sales. Shares rose 1.4% in European trading despite a recent trial failure, with the company reconfirming its $80bn 2030 revenue goal.
AstraZeneca's CEO Pascal Soriot warns the company must innovate at 'Chinese speed' to compete with emerging pharmaceutical rivals, citing the automotive industry's loss to Chinese electric vehicle dominance. Despite confidence in hitting $80bn 2030 sales targets, Soriot acknowledges the threat from Chinese innovators in novel drug technologies.
Hospital é condenado a pagar R$ 28 mil por aplicar vacina da Oxford/AstraZeneca após o vencimento e por assédio moral contra funcionária. A trabalhadora relatou angústia por quase três meses sem imunização adequada e humilhações verbais, sexuais e raciais.
AstraZeneca's experimental heart disease drug, Wainua, failed to meet its primary goal in a late-stage trial, causing its shares to drop significantly. Analysts cited potential loss of investor trust in management as a key concern, alongside reduced sales projections.
Акции AstraZeneca упали на 9% после того, как испытания нового сердечного препарата Wainua, разработанного совместно с Ionis, не показали значимых результатов. Препарат предназначался для лечения редкого заболевания сердца, поражающего до 500 тысяч человек. Провал испытаний приведет к снижению потенциальных продаж препарата.
AstraZeneca's stock dropped nearly 9% after its experimental heart disease drug, Wainua, failed to meet its primary target in a late-stage clinical trial. The drug, intended for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), did not significantly reduce deaths or heart emergencies compared to a placebo.
AstraZeneca's oral anti-obesity drug, elecoglipron, has shown promising results in a study, demonstrating a good safety and tolerability profile while leading to significant weight loss and appetite reduction.
AstraZeneca's oral anti-obesity pill, elecoglipron, shows promising results in a study, demonstrating a good safety and tolerance profile while inducing significant weight loss and appetite reduction.
